Cabaletta Bio Inc (CABA)

Apr 29, 2026

H.C. Wainwright reiterates Cabaletta Bio stock rating on manufacturing scalability - Investing.com Australia

Apr 29, 2026

Apr 29, 2026

Cabaletta Bio enters agreement with California company to manufacture one of its cell therapies - Pennsylvania Business Report -

Apr 29, 2026

Apr 28, 2026

Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK

Apr 28, 2026

Apr 28, 2026

Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma

Apr 28, 2026

Apr 28, 2026

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace

Apr 28, 2026

Apr 28, 2026

Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com South Africa

Apr 28, 2026

Apr 28, 2026

CABA Forms Agreement with Cellares for Cost-Effective Cell Thera - GuruFocus

Apr 28, 2026

Apr 28, 2026

CABA Gains Strategic Partnership for Efficient Rese-Cel Producti - GuruFocus

Apr 28, 2026

Apr 28, 2026

Cabaletta Bio | DEF 14A: Definitive information statements - Moomoo

Apr 28, 2026

Apr 28, 2026

Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com

Apr 28, 2026

Apr 28, 2026

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - The Manila Times

Apr 28, 2026

Apr 28, 2026

10-year rese-cel supply deal aims for thousands of patients a year - Stock Titan

Apr 28, 2026

Apr 28, 2026

Cabaletta Bio (NASDAQ: CABA) targets 600M authorized shares and equity plan changes - Stock Titan

Apr 28, 2026

Apr 28, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 28, 2026

Apr 27, 2026

Cabaletta Bio shares climb after insider purchases - MSN

Apr 27, 2026

Apr 27, 2026

Cabaletta Bio, Inc. to Present New Data on Rese-cel at ASGCT 2026 Annual Meeting - Quiver Quantitative

Apr 27, 2026

Apr 27, 2026

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting - The Manila Times

Apr 27, 2026

Apr 27, 2026

New autoimmune cell therapy data lead Cabaletta's Boston meeting talks - Stock Titan

Apr 27, 2026

Apr 24, 2026

OneIM Acquisition Corp. (OIM) - Minichart

Apr 24, 2026

Apr 23, 2026

Cabaletta (CABA) Moat Analysis | Cabaletta Bio Inc. beats EPS estimates by 15.6%High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 23, 2026

Cabaletta Bio slides on proposed securities offering - MSN

Apr 23, 2026

Apr 21, 2026

William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo

Apr 21, 2026

Apr 20, 2026

Cabaletta Bio’s Rese-cel: Transforming Autoimmune Disease Treatment with CD19-CAR T Cell Therapy, No Preconditioning, and Automated Manufacturing 1 - Minichart

Apr 20, 2026

Apr 20, 2026

Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans - TipRanks

Apr 20, 2026

Apr 20, 2026

Cabaletta Bio posts April 2026 corporate presentation highlighting rese-cel trial progress, no-preconditioning data and automated manufacturing plans - TradingView

Apr 20, 2026

Apr 20, 2026

Rese-cel data expands across autoimmune diseases at Cabaletta Bio (CABA) - Stock Titan

Apr 20, 2026

Apr 19, 2026

Cabaletta reports results, advances Rese-Cel autoimmune program - MSN

Apr 19, 2026

Apr 18, 2026

Wall Street Zen Downgrades Cabaletta Bio (NASDAQ:CABA) to Sell - MarketBeat

Apr 18, 2026

Apr 17, 2026

Cabaletta Bio (Nasdaq: CABA) asks shareholders to double authorized common stock - Stock Titan

Apr 17, 2026

Apr 17, 2026

CABA News | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill

Apr 17, 2026

Apr 15, 2026

Cellares’ Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy (CABA:NASDAQ) - Seeking Alpha

Apr 15, 2026

Apr 15, 2026

CABA: Cabaletta Bio Advances CAR T Cell Therapy with Cellares' Technology - GuruFocus

Apr 15, 2026

Apr 14, 2026

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - 01net

Apr 14, 2026

Apr 14, 2026

Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform - National Today

Apr 14, 2026

Apr 14, 2026

Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle - TipRanks

Apr 14, 2026

Apr 14, 2026

Cabaletta Bio's Rese-cel Made on Cellares' Platform Given to First Patients - marketscreener.com

Apr 14, 2026

Apr 14, 2026

First patients dosed with Cabaletta Bio's rese-cel manufactured on Cellares' automated cell shuttle(TM) platform - marketscreener.com

Apr 14, 2026

Apr 14, 2026

First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform - TradingView

Apr 14, 2026

Apr 14, 2026

Cellares and Cabaletta Bio Successfully Infuse First Patients with Rese-cel - Intellectia AI

Apr 14, 2026

Apr 13, 2026

Aug Retail: What is Cabaletta Bio Incs P E ratio telling usLayoff News & Fast Exit and Entry Trade Guides - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 13, 2026

Apr 13, 2026

Aug Wrap: Is Cabaletta Bio Inc stock trending bullishWeekly Stock Recap & Momentum Based Trading Ideas - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Cabaletta Bio (CABA) upgraded to buy: Here's what you should know - MSN

Apr 12, 2026

Apr 11, 2026

Institution Moves: Whats the MACD signal for Cabaletta Bio IncLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Cabaletta Bio, Inc. $CABA Position Raised by JPMorgan Chase & Co. - MarketBeat

Apr 10, 2026

Apr 09, 2026

Cabaletta Bio, Inc. (CABA) Stock Forecasts - Yahoo! Finance Canada

Apr 09, 2026

Apr 09, 2026

Volume Report: Can Cabaletta Bio Inc deliver consistent dividendsMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn

Apr 09, 2026